Apellis Pharmaceuticals Insider Sold Shares Worth $412,296, According to a Recent SEC Filing

MT Newswires04:32

Wedbush Raises Price Target on Apellis Pharmaceuticals to $30 From $25, Keeps Neutral Rating

MT NewswiresJan 23 20:38 · Ratings

RBC Capital Reiterates Sector Perform on Apellis Pharmaceuticals, Maintains $26 Price Target

BenzingaJan 22 01:05 · Ratings

A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $31 to $47

Futu NewsJan 15 21:00 · Ratings

A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $32 to $60

Futu NewsJan 14 21:00 · Ratings

Apellis Pharmaceuticals Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow JonesJan 14 20:54 · Ratings